Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Mark R Bray"'
Autor:
Omid Hamid, Siqing Fu, Manish Sharma, Anna Spreafico, Kyriakos P Papadopoulos, Erika Hamilton, Alexander Spira, Quincy Chu, Brigette Ma, Emily Roberts-Thomson, Dih-Yih Chen, Judy S Wang, Scott A Laurie, Mark R Bray, Roger Sidhu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b9d18b36b4844c1ab02ca1daf51708cf
Autor:
Shawn P. Kubli, Larsen Vornholz, Gordon Duncan, Wenjing Zhou, Parameswaran Ramachandran, Jerome Fortin, Maureen Cox, SeongJun Han, Robert Nechanitzky, Duygu Nechanitzky, Bryan E. Snow, Lisa Jones, Wanda Y. Li, Jillian Haight, Andrew Wakeham, Mark R. Bray, Tak W. Mak
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Myeloid cells modulate the immune response within the tumour microenvironment, but the underlying mechanisms remain largely unknown. Here, the authors show that Fcmr – the putative receptor for soluble IgM – is a potent negative regulator of anti
Externí odkaz:
https://doaj.org/article/249fbfe56ab6438d997eb47907be7294
Autor:
Cerise Yuen‐Ki Chan, Vincent Wai‐Hin Yuen, David Kung‐Chun Chiu, Chi‐Ching Goh, Kelsie L. Thu, David W. Cescon, Isabel Soria‐Bretones, Cheuk‐Ting Law, Jacinth Wing‐Sum Cheu, Derek Lee, Aki Pui‐Wah Tse, Kel Vin Tan, Misty Shuo Zhang, Bowie Po‐Yee Wong, Chun‐Ming Wong, Pek‐Lan Khong, Irene Oi‐Lin Ng, Mark R. Bray, Tak Wah Mak, Thomas Chung‐Cheung Yau, Carmen Chak‐Lui Wong
Publikováno v:
Hepatology. 77:729-744
Prognosis of HCC remains poor due to lack of effective therapies. Immune checkpoint inhibitors (ICIs) have delayed response and are only effective in a subset of patients. Treatments that could effectively shrink the tumors within a short period of t
Autor:
Edward Ayoub, Akhil Marupudi, Yuki Nishida, Rafael Heinz Montoya, Vakul Mohanty, Wencke Walter, Mark R Bray, Tallie Patsilevas, Steffen Boettcher, Ghayas C. Issa, Ken Chen, Torsten Haferlach, Gautam Borthakur, Michael Andreeff
Publikováno v:
Blood. 140:5941-5943
Autor:
John J. Tentler, Graham C. Fletcher, Mark R. Bray, Todd M. Pitts, Marileila Varella-Garcia, Maria I. Kachaeva, Kelsey L. Brunkow, Heather M. Selby, Timothy P. Newton, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond
Purpose: The Aurora kinases are a family of conserved serine-threonine kinases with key roles in mitotic cell division. As with other promising anticancer targets, patient selection strategies to identify a responsive subtype will likely be required
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5324865906834c4f5520e25ff32c3bd7
https://doi.org/10.1158/1078-0432.c.6520646.v1
https://doi.org/10.1158/1078-0432.c.6520646.v1
Autor:
Mark R. Bray, Carolyn F. Sidor, William E. Fogler, Stacy M. Plum, Todd A. Hembrough, Trisha A. Denny, Richard D. Brokx, Graham C. Fletcher
Supplementary Table 1, Supplementary Figures 1-4 from ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7587d228d580a20eca5f02f25fd05803
https://doi.org/10.1158/1535-7163.22484309.v1
https://doi.org/10.1158/1535-7163.22484309.v1
Autor:
Mark R. Bray, Carolyn F. Sidor, William E. Fogler, Stacy M. Plum, Todd A. Hembrough, Trisha A. Denny, Richard D. Brokx, Graham C. Fletcher
ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival: angiogenesis, proliferation, and the cell cycle. ENMD-2076 has selective activity against the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9a7ae9d78aa981d9140702e0585e01
https://doi.org/10.1158/1535-7163.c.6531383
https://doi.org/10.1158/1535-7163.c.6531383
Autor:
John J. Tentler, Graham C. Fletcher, Mark R. Bray, Todd M. Pitts, Marileila Varella-Garcia, Maria I. Kachaeva, Kelsey L. Brunkow, Heather M. Selby, Timothy P. Newton, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond
PDF file - 173K, Phospho-receptor tyrosine kinase (phospho-RTK) array analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::665621d6b77185e7e2dfd022c8990875
https://doi.org/10.1158/1078-0432.22446101
https://doi.org/10.1158/1078-0432.22446101
Autor:
John J. Tentler, Graham C. Fletcher, Mark R. Bray, Todd M. Pitts, Marileila Varella-Garcia, Maria I. Kachaeva, Kelsey L. Brunkow, Heather M. Selby, Timothy P. Newton, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond
PDF file - 224K, Gene Set Enrichment Analysis (GSEA) of ENMD-2076 sensitivity including all breast cancer subtypes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e323ce62705ddcd9be0dc5c0d03f418
https://doi.org/10.1158/1078-0432.22446095.v1
https://doi.org/10.1158/1078-0432.22446095.v1
Autor:
Geoffrey I. Shapiro, Wells Messersmith, Carolyn Sidor, Mark R. Bray, Jamie Arnott, Mark Morrow, Gillian N. Kulikowski, Todd M. Pitts, Graham C. Fletcher, Shuchi S. Pandya, Eunice L. Kwak, S. Gail Eckhardt, Daniel L. Gustafson, Ryan J. Hansen, Bruno R. Bastos, Jennifer R. Diamond
Purpose: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity.Experiment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d572863a9a66aa1349c1b07bdf1a44
https://doi.org/10.1158/1078-0432.c.6518136.v1
https://doi.org/10.1158/1078-0432.c.6518136.v1